The National Health Service (NHS) in England has announced a significant advancement in cancer treatment by offering a subcutaneous injection of the immunotherapy drug pembrolizumab. This new formulation, administered in under one minute, replaces the traditional intravenous infusion that could take up to an hour. The change is expected to benefit thousands of patients by reducing time spent in hospitals and improving overall treatment experience.
Pembrolizumab, marketed as Keytruda, is a checkpoint inhibitor that helps the immune system recognize and attack cancer cells. It is used to treat various cancers, including melanoma, lung cancer, and Hodgkin lymphoma. The new injection formulation, known as pembrolizumab subcutaneous, was developed by Merck & Co., which also manufactures the intravenous version. Clinical trials have shown that the subcutaneous injection is as effective as the infusion, with similar safety profiles.
The rollout by the NHS marks a shift towards more patient-friendly cancer care. Patients will no longer need to sit for prolonged periods in infusion chairs, freeing up hospital resources and reducing waiting times. The faster administration also allows for more flexible scheduling, potentially enabling patients to undergo treatment during shorter visits. This is particularly beneficial for those with mobility issues or those who live far from treatment centers.
The introduction of this injection aligns with broader trends in oncology to streamline treatment delivery. For companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI), which are developing novel immunotherapies, the success of pembrolizumab subcutaneous underscores the importance of improving drug delivery mechanisms to enhance patient adherence and outcomes.
The NHS estimates that thousands of patients will receive the injection annually, reducing the burden on healthcare systems. The drug is administered via a prefilled syringe, and healthcare professionals are being trained in the new technique. The transition is expected to occur over the coming months, with full implementation by 2025.
This development is part of a larger effort by the NHS to adopt innovative cancer treatments. Other immunotherapies, such as nivolumab and atezolizumab, are also being explored in subcutaneous formulations. The success of pembrolizumab subcutaneous could pave the way for similar approvals in other countries, benefiting patients worldwide.
For more information on this and related developments, visit BioMedWire.